siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury

Bruce Molitoris, Pierre Dagher, Ruben M. Sandoval, Silvia Campos-Bilderback, Hagit Ashush, Eduard Fridman, Anat Brafman, Alexander Faerman, Simon J. Atkinson, James D. Thompson, Hagar Kalinski, Rami Skaliter, Shai Erlich, Elena Feinstein

Research output: Contribution to journalArticle

194 Citations (Scopus)

Abstract

Proximal tubule cells (PTCs), which are the primary site of kidney injury associated with ischemia or nephrotoxicity, are the site of oligonucleotide reabsorption within the kidney. We exploited this property to test the efficacy of siRNA targeted to p53, a pivotal protein in the apoptotic pathway, to prevent kidney injury. Naked synthetic siRNA to p53 injected intravenously 4 h after ischemic injury maximally protected both PTCs and kidney function. PTCs were the primary site for siRNA uptake within the kidney and body. Following glomerular filtration, endocytic uptake of Cy3-siRNA by PTCs was rapid and extensive, and significantly reduced ischemia-induced p53 upregulation. The duration of the siRNA effect in PTCs was 24 to 48 h, determined by levels of p53 mRNA and protein expression. Both Cy3 fluorescence and in situ hybridization of siRNA corroborated a short t1/2 for siRNA. The extent of renoprotection, decrease in cellular p53 and attenuation of p53-mediated apoptosis by siRNA were dose- and time-dependent. Analysis of renal histology and apoptosis revealed improved injury scores in both cortical and corticomedullary regions. siRNA to p53 was also effective in a model of cisplatininduced kidney injury. Taken together, these data indicate that rapid delivery of siRNA to proximal tubule cells follows intravenous administration. Targeting siRNA to p53 leads to a dose-dependent attenuation of apoptotic signaling, suggesting potential therapeutic benefit for ischemic and nephrotoxic kidney injury.

Original languageEnglish
Pages (from-to)1754-1764
Number of pages11
JournalJournal of the American Society of Nephrology
Volume20
Issue number8
DOIs
StatePublished - Aug 2009

Fingerprint

Acute Kidney Injury
Small Interfering RNA
Cisplatin
Kidney
Wounds and Injuries
Ischemia
Apoptosis
Proximal Kidney Tubule
Fluorescence In Situ Hybridization
Oligonucleotides
Intravenous Administration
Histology
Proteins
Up-Regulation
Messenger RNA

ASJC Scopus subject areas

  • Nephrology

Cite this

siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. / Molitoris, Bruce; Dagher, Pierre; Sandoval, Ruben M.; Campos-Bilderback, Silvia; Ashush, Hagit; Fridman, Eduard; Brafman, Anat; Faerman, Alexander; Atkinson, Simon J.; Thompson, James D.; Kalinski, Hagar; Skaliter, Rami; Erlich, Shai; Feinstein, Elena.

In: Journal of the American Society of Nephrology, Vol. 20, No. 8, 08.2009, p. 1754-1764.

Research output: Contribution to journalArticle

Molitoris, B, Dagher, P, Sandoval, RM, Campos-Bilderback, S, Ashush, H, Fridman, E, Brafman, A, Faerman, A, Atkinson, SJ, Thompson, JD, Kalinski, H, Skaliter, R, Erlich, S & Feinstein, E 2009, 'siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury', Journal of the American Society of Nephrology, vol. 20, no. 8, pp. 1754-1764. https://doi.org/10.1681/ASN.2008111204
Molitoris, Bruce ; Dagher, Pierre ; Sandoval, Ruben M. ; Campos-Bilderback, Silvia ; Ashush, Hagit ; Fridman, Eduard ; Brafman, Anat ; Faerman, Alexander ; Atkinson, Simon J. ; Thompson, James D. ; Kalinski, Hagar ; Skaliter, Rami ; Erlich, Shai ; Feinstein, Elena. / siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. In: Journal of the American Society of Nephrology. 2009 ; Vol. 20, No. 8. pp. 1754-1764.
@article{bc4f7f7b5049416e9ee4ded92bae2160,
title = "siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury",
abstract = "Proximal tubule cells (PTCs), which are the primary site of kidney injury associated with ischemia or nephrotoxicity, are the site of oligonucleotide reabsorption within the kidney. We exploited this property to test the efficacy of siRNA targeted to p53, a pivotal protein in the apoptotic pathway, to prevent kidney injury. Naked synthetic siRNA to p53 injected intravenously 4 h after ischemic injury maximally protected both PTCs and kidney function. PTCs were the primary site for siRNA uptake within the kidney and body. Following glomerular filtration, endocytic uptake of Cy3-siRNA by PTCs was rapid and extensive, and significantly reduced ischemia-induced p53 upregulation. The duration of the siRNA effect in PTCs was 24 to 48 h, determined by levels of p53 mRNA and protein expression. Both Cy3 fluorescence and in situ hybridization of siRNA corroborated a short t1/2 for siRNA. The extent of renoprotection, decrease in cellular p53 and attenuation of p53-mediated apoptosis by siRNA were dose- and time-dependent. Analysis of renal histology and apoptosis revealed improved injury scores in both cortical and corticomedullary regions. siRNA to p53 was also effective in a model of cisplatininduced kidney injury. Taken together, these data indicate that rapid delivery of siRNA to proximal tubule cells follows intravenous administration. Targeting siRNA to p53 leads to a dose-dependent attenuation of apoptotic signaling, suggesting potential therapeutic benefit for ischemic and nephrotoxic kidney injury.",
author = "Bruce Molitoris and Pierre Dagher and Sandoval, {Ruben M.} and Silvia Campos-Bilderback and Hagit Ashush and Eduard Fridman and Anat Brafman and Alexander Faerman and Atkinson, {Simon J.} and Thompson, {James D.} and Hagar Kalinski and Rami Skaliter and Shai Erlich and Elena Feinstein",
year = "2009",
month = "8",
doi = "10.1681/ASN.2008111204",
language = "English",
volume = "20",
pages = "1754--1764",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "8",

}

TY - JOUR

T1 - siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury

AU - Molitoris, Bruce

AU - Dagher, Pierre

AU - Sandoval, Ruben M.

AU - Campos-Bilderback, Silvia

AU - Ashush, Hagit

AU - Fridman, Eduard

AU - Brafman, Anat

AU - Faerman, Alexander

AU - Atkinson, Simon J.

AU - Thompson, James D.

AU - Kalinski, Hagar

AU - Skaliter, Rami

AU - Erlich, Shai

AU - Feinstein, Elena

PY - 2009/8

Y1 - 2009/8

N2 - Proximal tubule cells (PTCs), which are the primary site of kidney injury associated with ischemia or nephrotoxicity, are the site of oligonucleotide reabsorption within the kidney. We exploited this property to test the efficacy of siRNA targeted to p53, a pivotal protein in the apoptotic pathway, to prevent kidney injury. Naked synthetic siRNA to p53 injected intravenously 4 h after ischemic injury maximally protected both PTCs and kidney function. PTCs were the primary site for siRNA uptake within the kidney and body. Following glomerular filtration, endocytic uptake of Cy3-siRNA by PTCs was rapid and extensive, and significantly reduced ischemia-induced p53 upregulation. The duration of the siRNA effect in PTCs was 24 to 48 h, determined by levels of p53 mRNA and protein expression. Both Cy3 fluorescence and in situ hybridization of siRNA corroborated a short t1/2 for siRNA. The extent of renoprotection, decrease in cellular p53 and attenuation of p53-mediated apoptosis by siRNA were dose- and time-dependent. Analysis of renal histology and apoptosis revealed improved injury scores in both cortical and corticomedullary regions. siRNA to p53 was also effective in a model of cisplatininduced kidney injury. Taken together, these data indicate that rapid delivery of siRNA to proximal tubule cells follows intravenous administration. Targeting siRNA to p53 leads to a dose-dependent attenuation of apoptotic signaling, suggesting potential therapeutic benefit for ischemic and nephrotoxic kidney injury.

AB - Proximal tubule cells (PTCs), which are the primary site of kidney injury associated with ischemia or nephrotoxicity, are the site of oligonucleotide reabsorption within the kidney. We exploited this property to test the efficacy of siRNA targeted to p53, a pivotal protein in the apoptotic pathway, to prevent kidney injury. Naked synthetic siRNA to p53 injected intravenously 4 h after ischemic injury maximally protected both PTCs and kidney function. PTCs were the primary site for siRNA uptake within the kidney and body. Following glomerular filtration, endocytic uptake of Cy3-siRNA by PTCs was rapid and extensive, and significantly reduced ischemia-induced p53 upregulation. The duration of the siRNA effect in PTCs was 24 to 48 h, determined by levels of p53 mRNA and protein expression. Both Cy3 fluorescence and in situ hybridization of siRNA corroborated a short t1/2 for siRNA. The extent of renoprotection, decrease in cellular p53 and attenuation of p53-mediated apoptosis by siRNA were dose- and time-dependent. Analysis of renal histology and apoptosis revealed improved injury scores in both cortical and corticomedullary regions. siRNA to p53 was also effective in a model of cisplatininduced kidney injury. Taken together, these data indicate that rapid delivery of siRNA to proximal tubule cells follows intravenous administration. Targeting siRNA to p53 leads to a dose-dependent attenuation of apoptotic signaling, suggesting potential therapeutic benefit for ischemic and nephrotoxic kidney injury.

UR - http://www.scopus.com/inward/record.url?scp=68049136123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049136123&partnerID=8YFLogxK

U2 - 10.1681/ASN.2008111204

DO - 10.1681/ASN.2008111204

M3 - Article

C2 - 19470675

AN - SCOPUS:68049136123

VL - 20

SP - 1754

EP - 1764

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 8

ER -